Brief: Nexalis Therapeutics Signs Funding Partnership With Point8 Capital To Replace Existing Facility
28/05/2026 01:54
BRIEF-Nexalis Therapeutics Signs Funding Partnership With Point8 Capital To Replace Existing Facility May 28 (Reuters) - Nexalis Therapeutics Ltd NX1.AX:
SIGNS FUNDING PARTNERSHIP WITH POINT8 CAPITAL TO REPLACE EXISTING FACILITY
SECURES UP TO A$53 MILLION NON-DILUTIVE FUNDING ACROSS THREE SUB-FACILITIES
Further company coverage: NX1.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalis Therapeutics
See all newsBrief: Nexalis Therapeutics Says Sean Williams Has Resigned As Non-Executive Chairman
Brief: Nexalis Therapeutics Signs Funding Partnership With Point8 Capital To Replace Existing Facility
Brief: Nexalis Therapeutics Seeks Trading Halt
Brief: Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment
Australia's Nexalis Therapeutics gains most in over 6 months on trial approval